Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
基本信息
- 批准号:8704412
- 负责人:
- 金额:$ 32.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-19 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAllelesAntigen ReceptorsB Cell ProliferationB-Cell DevelopmentB-LymphocytesBerylliumBindingBypassCatalogingCatalogsCellsCollectionComplexCritical PathwaysDataDevelopmentDiagnosticDiseaseDisease ProgressionElementsGenesGeneticGrowthHumanImmuneImmune responseImmune systemIndiumKnowledgeLesionLeukocytesLinkLymphocyteLymphocyte ActivationLymphocyte FunctionLymphoidLymphomaLymphomagenesisMalignant NeoplasmsMammalian CellMolecularMolecular DiagnosisMolecular TargetMusMutationNormal tissue morphologyOncogenicPathway interactionsPatientsPhysiologyProcessProteinsReceptor CellReceptor SignalingReceptors, Antigen, B-CellRecruitment ActivityRegulationRoleSamplingScaffolding ProteinSignal TransductionSignaling MoleculeSignaling ProteinT-Cell ReceptorT-LymphocyteTestingTherapeuticUbiquitinationVariantWorkbasecell behaviorcofactordesigngain of functioninnovationinsightlarge cell Diffuse non-Hodgkin&aposs lymphomaleukemia/lymphomaloss of functionmutantnew therapeutic targetnovelnovel diagnosticsoverexpressionpathogenprotein functionpublic health relevancereceptorscaffoldtherapy designubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): Antigen receptor signaling to NF-?B is a highly regulated, critical pathway for B and T lymphocyte activation during the adaptive immune response. NF-?B controls many genes required for lymphocyte function including genes that promote proliferation and survival. The inappropriate activation of NF-?B is associated with multiple leukemias and lymphomas, which frequently acquire mutations in signaling molecules that elicit their receptor- independent constitutive NF-?B activity. CARD11 (CARMA1) is a key scaffold protein that functions in both T cell receptor and B cell receptor pathways to transmit signals from the engaged receptor to the activation of the IKK complex and NF-?B. Aberrant CARD11-dependent signaling is required for the dysregulated proliferation of the activated B cell-like (ABC) subtype of Diffuse Large B Cell Lymphoma (DLBCL), and mutations in CARD11, which hyperactivate the protein, are found in ~10% of patient samples of ABC DLBCL. Previous work has established that during normal signaling, CARD11 undergoes a transition from an inactive to an active signaling scaffold that recruits several signaling cofactors into a complex that induces IKK activity. An Inhibitory Domain (ID) in CARD11 controls this transition; it keeps CARD11 inactive in the basal state, but receives signals from the engaged receptor that neutralize its inhibitory action and allow CARD11 to signal. However, it remains poorly understood how activated CARD11 signals to NF-?B, how precisely the ID functions, how lymphoma-associated mutations hyperactivate CARD11, and how aberrant CARD11 signaling causes disease. In this application, we will 1) characterize a novel collection of gain-of-function
and loss-of- function CARD11 variants to define critical mechanisms of normal and oncogenic CARD11 signaling; 2) determine the mechanistic basis for how the Inhibitory Domain of CARD11 governs signal-dependent CARD11 activation; 3) test the hypothesis that hyperactive CARD11 is sufficient to alter B cell development and promote unwarranted B cell proliferation; and 4) characterize novel CARD11 signaling cofactors that we have recently identified. Our studies will help illuminate how signaling proteins, especially scaffolds, employ autoinhibitory mechanisms to allow their signal-induced activation, and how cancers exploit these mechanisms by selecting for mutations that bypass regulation to promote proliferation and survival. In addition, our results are likely to provide a catalogue of mutations that could underle the development of lymphomas in humans and therefore offer novel diagnostic insight and opportunities. Finally, our studies should reveal previously unrecognized molecular targets for the development of new therapies designed to treat NF-?B-dependent cancers and other diseases that result from aberrant immune cell behavior.
描述(由申请人提供):抗原受体向NF-?B是一个高度调控的,在适应性免疫反应中B和T淋巴细胞活化的关键途径。NF - ?B控制淋巴细胞功能所需的许多基因,包括促进增殖和存活的基因。NF-?的不当激活B与多发性白血病和淋巴瘤有关,这两种疾病在信号分子中经常发生突变,从而引发与受体无关的构成性NF-?B的活动。CARD11 (CARMA1)是一个关键的支架蛋白,在T细胞受体和B细胞受体途径中发挥作用,将信号从参与受体传递到IKK复合物和NF- B的激活。漫漫性大B细胞淋巴瘤(DLBCL)活化的B细胞样(ABC)亚型的增殖失调需要异常的CARD11依赖信号,并且在约10%的ABC DLBCL患者样本中发现了CARD11突变,该突变使该蛋白过度激活。先前的研究已经证实,在正常的信号传导过程中,CARD11经历了从一个不活跃的信号传导支架到一个活跃的信号传导支架的转变,它将几个信号传导辅助因子招募到一个诱导IKK活性的复合体中。CARD11中的抑制结构域(ID)控制着这种转变;它使CARD11在基础状态下保持非活性,但接收来自参与受体的信号,该受体中和其抑制作用并允许CARD11发出信号。然而,对于激活CARD11如何向NF-?B, ID如何精确地起作用,淋巴瘤相关突变如何过度激活CARD11,以及异常的CARD11信号如何导致疾病。在这个应用程序中,我们将1)描述一个新的功能增益集合
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joel L Pomerantz其他文献
Joel L Pomerantz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joel L Pomerantz', 18)}}的其他基金
Targeting a Membrane Protease that Controls NK Cell Maturation
靶向控制 NK 细胞成熟的膜蛋白酶
- 批准号:
10631217 - 财政年份:2022
- 资助金额:
$ 32.61万 - 项目类别:
Targeting a Membrane Protease that Controls NK Cell Maturation
靶向控制 NK 细胞成熟的膜蛋白酶
- 批准号:
10506509 - 财政年份:2022
- 资助金额:
$ 32.61万 - 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
- 批准号:
10063977 - 财政年份:2019
- 资助金额:
$ 32.61万 - 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
- 批准号:
10528445 - 财政年份:2019
- 资助金额:
$ 32.61万 - 项目类别:
Mechanisms of Control of Lymphocyte Activation and Proliferation by a Critical Signaling Integrator
关键信号整合器控制淋巴细胞激活和增殖的机制
- 批准号:
10304147 - 财政年份:2019
- 资助金额:
$ 32.61万 - 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
- 批准号:
9056446 - 财政年份:2013
- 资助金额:
$ 32.61万 - 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
- 批准号:
8829795 - 财政年份:2013
- 资助金额:
$ 32.61万 - 项目类别:
Regulation of CARD11 signaling in normal and dysregulated lymphocyte development
CARD11 信号在正常和失调淋巴细胞发育中的调节
- 批准号:
8554256 - 财政年份:2013
- 资助金额:
$ 32.61万 - 项目类别:
Motor protein regulation of T cell receptor signaling
T 细胞受体信号传导的运动蛋白调节
- 批准号:
8099462 - 财政年份:2009
- 资助金额:
$ 32.61万 - 项目类别:
Motor protein regulation of T cell receptor signaling
T 细胞受体信号传导的运动蛋白调节
- 批准号:
7648345 - 财政年份:2009
- 资助金额:
$ 32.61万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 32.61万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 32.61万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 32.61万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 32.61万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 32.61万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 32.61万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 32.61万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 32.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 32.61万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 32.61万 - 项目类别: